0001213900-21-036321.txt : 20210709
0001213900-21-036321.hdr.sgml : 20210709
20210709150525
ACCESSION NUMBER: 0001213900-21-036321
CONFORMED SUBMISSION TYPE: D
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: 06b
FILED AS OF DATE: 20210709
DATE AS OF CHANGE: 20210709
EFFECTIVENESS DATE: 20210709
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: Boston Therapeutics, Inc.
CENTRAL INDEX KEY: 0001473579
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 270801073
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: D
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-405753
FILM NUMBER: 211082672
BUSINESS ADDRESS:
STREET 1: 354 MERRIMACK STREET
STREET 2: #4
CITY: LAWRENCE
STATE: MA
ZIP: 01843
BUSINESS PHONE: (603) 935-9799
MAIL ADDRESS:
STREET 1: 354 MERRIMACK STREET
STREET 2: #4
CITY: LAWRENCE
STATE: MA
ZIP: 01843
FORMER COMPANY:
FORMER CONFORMED NAME: AVANYX Therapeutics, Inc.
DATE OF NAME CHANGE: 20091001
D
1
primary_doc.xml
X0708
D
LIVE
0001473579
Boston Therapeutics, Inc.
354 MERRIMACK STREET #4
LAWRENCE
MA
MASSACHUSETTS
01843
603-935-9799
DELAWARE
None
AVANYX Therapeutics, Inc.
Corporation
true
David
Ludvigson
354 MERRIMACK STREET #4
Lawrence
MA
MASSACHUSETTS
01843
Executive Officer
Director
Conroy
Chi-Heng
Cheng
354 MERRIMACK STREET #4
Lawrence
MA
MASSACHUSETTS
01843
Director
Biotechnology
Decline to Disclose
- 06b
false
2021-06-25
false
true
true
true
Convertible Note and Warrrants
false
0
8434778
8434778
0
false
5
0
0
0
false
Boston Therapeutics, Inc.
/s/ David Ludvigson
David Ludvigson
Chief Executive Officer
2021-07-09